Humanistic burden of mucopolysaccharidoses: a systematic literature review

被引:3
作者
Li, Joyce Wai-Yin [1 ]
Yan, Kevin [1 ]
Balijepalli, Chakrapani [1 ]
Druyts, Eric [1 ,2 ]
机构
[1] Pharmalyt Grp, Vancouver, BC, Canada
[2] Pharmalyt Grp, 422 Richards St,Suite 170, Vancouver, BC V6B 2Z4, Canada
关键词
Mucopolysaccharidoses; systematic review; humanistic burden; quality-of-life; health-related quality-of-life; ENZYME REPLACEMENT THERAPY; QUALITY-OF-LIFE; MORQUIO; HEALTH; EXPERIENCE; OUTCOMES; ALPHA; VI;
D O I
10.1080/03007995.2024.2316213
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ObjectiveTo systematically review the literature and summarize the health-related quality-of-life (HRQoL) of patients undergoing treatment for mucopolysaccharidoses (MPS), a rare, hereditary lysosomal storage disorder.MethodsA systematic review was performed in accordance with PRISMA guidelines to identify research studies that describe the humanistic burden of MPS. A comprehensive literature search was conducted in EMBASE, MEDLINE, and eligible conferences were screened to include applicable abstracts.ResultsOf 870 identified articles, 15 studies reported the HRQoL burden of patients with MPS undergoing or with a history of ERT and/or HSCT. These studies include patients of MPS I (n = 2), MPS II (n = 4), MPS IV (n = 6), MPS VI (n = 1), and subtype not mentioned (n = 2). Although the quality-of-life of MPS patients is influenced by time of diagnosis, pain, cognitive involvement, severity of disease, mobility, dependence, and time of treatment initiation, the HRQoL scores of MPS patients across all the scales were below the median reference population scores across all dimensions. This is seen in comparison to healthy participants but also in comparison to patients with other chronic illnesses. The multi-organ involvement, neurological impairment, pain, and morbidity associated with the condition not only affects activity of daily living but also affects social functioning, emotional status, employment status among adults, and school functioning among children.ConclusionsThis systematic literature review revealed the substantial humanistic burden of individuals affected by MPS as well as caregivers. Significant variation in HRQoL scores was observed, however studies indicate that the quality-of-life of MPS patients is influenced primarily by severity of disease (MPS type and phenotype), and then by time of diagnosis, pain, cognitive involvement, mobility, dependence, and time of treatment initiation. Further studies are needed to assess the global humanistic burden of MPS, particularly in MPS III, VI, VII, and IX subtypes, in adults, and for a longer follow-up period. Considering the vast array of HRQoL assessment tools available and used in this study, researchers should also consider using scales with condition-specific measures to ensure appropriate estimates of effectiveness.
引用
收藏
页码:709 / 722
页数:14
相关论文
共 33 条
  • [11] Genistein supplementation in patients affected by Sanfilippo disease
    Delgadillo, Veronica
    del Mar O'Callaghan, Maria
    Artuch, Rafael
    Montero, Raquel
    Pineda, Mercedes
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 (05) : 1039 - 1044
  • [12] 30 months follow-up of an early enzyme replacement therapy in a severe Morquio A patient: About one case
    Do Cao, J.
    Wiedemann, A.
    Quinaux, T.
    Battaglia-Hsu, S. F.
    Mainard, L.
    Froissart, R.
    Bonnemains, C.
    Ragot, S.
    Leheup, B.
    Journeau, P.
    Feillet, F.
    [J]. MOLECULAR GENETICS AND METABOLISM REPORTS, 2016, 9 : 42 - 45
  • [13] Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study
    Guffon, Nathalie
    Heron, Benedicte
    Chabrol, Brigitte
    Feillet, Francois
    Montauban, Vincent
    Valayannopoulos, Vassili
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2015, 10
  • [14] Enzyme replacement therapy for mucopolysaccharidosis VI: A Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study
    Harmatz, Paul
    Giugliani, Roberto
    Schwariz, Ida
    Guffon, Nathaue
    Teles, Eusa Leao
    Miranda, M. Clara Sa
    Wraith, J. Edmond
    Beck, Michael
    Arash, Lapp
    Scarpa, Maurilo
    Yu, Zi-Fan
    Wittes, Janet
    Berger, Kenneth I.
    Newman, Mary S.
    Lowe, Ann M.
    Kakkis, Emil
    Swiedler, Stuart J.
    [J]. JOURNAL OF PEDIATRICS, 2006, 148 (04) : 533 - 539
  • [15] Impact of elosulfase alfa in patients with morquio A syndrome who have limited ambulation: An open-label, phase 2 study
    Harmatz, Paul R.
    Mengel, Eugen
    Geberhiwot, Tarekegn
    Muschol, Nicole
    Hendriksz, Christian J.
    Burton, Barbara K.
    Jameson, Elisabeth
    Berger, Kenneth I.
    Jester, Andrea
    Treadwell, Marsha
    Sisic, Zlatko
    Decker, Celeste
    [J]. AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2017, 173 (02) : 375 - 383
  • [16] Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey
    Hendriksz, Christian J.
    Lavery, Christine
    Coker, Mahmut
    Ucar, Sema Kalkan
    Jain, Mohit
    Bell, Lisa
    Lampe, Christina
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2014, 9
  • [17] A complete deficiency of Hyaluronoglucosaminidase 1 (HYAL1) presenting as familial juvenile idiopathic arthritis
    Imundo, Lisa
    Leduc, Charles A.
    Guha, Saurav
    Brown, Marc
    Perino, Giorgio
    Gushulak, Lara
    Triggs-Raine, Barbara
    Chung, Wendy K.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 (05) : 1013 - 1022
  • [18] Lampe Christina, 2015, J. inborn errors metab. screen., V3, pe140016, DOI 10.1177/2326409815576188
  • [19] Liberati A, 2009, BMJ-BRIT MED J, V339, DOI [10.1136/bmj.b2700, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007, 10.1016/j.ijsu.2010.07.299, 10.1136/bmj.b2535, 10.1186/2046-4053-4-1, 10.1136/bmj.i4086]
  • [20] Clinical course of sly syndrome (mucopolysaccharidosis type VII)
    Montano, Adriana M.
    Lock-Hock, Ngu
    Steiner, Robert D.
    Graham, Brett H.
    Szlago, Marina
    Greenstein, Robert
    Pineda, Mercedes
    Gonzalez-Meneses, Antonio
    Coker, Mahmut
    Bartholomew, Dennis
    Sands, Mark S.
    Wang, Raymond
    Giugliani, Roberto
    Macaya, Alfons
    Pastores, Gregory
    Ketko, Anastasia K.
    Ezgu, Fatih
    Tanaka, Akemi
    Arash, Laila
    Beck, Michael
    Falk, Rena E.
    Bhattacharya, Kaustuv
    Franco, Jose
    White, Klane K.
    Mitchell, Grant A.
    Cimbalistiene, Loreta
    Holtz, Max
    Sly, William S.
    [J]. JOURNAL OF MEDICAL GENETICS, 2016, 53 (06) : 403 - 418